PriceTargets.com logo

Lisata Therapeutics - LSTA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 455.56%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.70 As of 04/19/2024 01:00 AM ET
▼ -0.15 (-5.26%)

This chart shows the closing price for LSTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lisata Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LSTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LSTA

Analyst Price Target is $15.00
▲ +455.56% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Lisata Therapeutics in the last 3 months. The average price target is $15.00, with a high forecast of $15.00 and a low forecast of $15.00. The average price target represents a 455.56% upside from the last price of $2.70.

This chart shows the closing price for LSTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Lisata Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
1/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
3/31/2023HC WainwrightReiterated RatingBuy$15.00Low
10/19/2022HC WainwrightBoost TargetBuy$6.00 ➝ $15.00Low
10/3/2022Brookline Capital ManagementReiterated RatingBuyLow
(Data available from 4/20/2019 forward)

News Sentiment Rating

0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2023
  • 5 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Lisata Therapeutics logo
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Read More

Today's Range

Now: $2.70
Low: $2.67
High: $2.87

50 Day Range

MA: $3.03
Low: $2.70
High: $3.35

52 Week Range

Now: $2.70
Low: $1.95
High: $4.53

Volume

1,975 shs

Average Volume

13,290 shs

Market Capitalization

$22.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Lisata Therapeutics?

The following sell-side analysts have issued stock ratings on Lisata Therapeutics in the last year: HC Wainwright.
View the latest analyst ratings for LSTA.

What is the current price target for Lisata Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Lisata Therapeutics in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 455.6%. HC Wainwright has the highest price target set, predicting LSTA will reach $15.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $15.00 for Lisata Therapeutics in the next year.
View the latest price targets for LSTA.

What is the current consensus analyst rating for Lisata Therapeutics?

Lisata Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LSTA will outperform the market and that investors should add to their positions of Lisata Therapeutics.
View the latest ratings for LSTA.

What other companies compete with Lisata Therapeutics?

Other companies that are similar to Lisata Therapeutics include Iterum Therapeutics, Addex Therapeutics, DURECT, Oncternal Therapeutics and Indaptus Therapeutics. Learn More about companies similar to Lisata Therapeutics.

How do I contact Lisata Therapeutics' investor relations team?

Lisata Therapeutics' physical mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The company's listed phone number is (908) 842-0100 and its investor relations email address is [email protected]. The official website for Lisata Therapeutics is www.caladrius.com. Learn More about contacing Lisata Therapeutics investor relations.